TERN Stock Risk & Deep Value Analysis
Terns Pharmaceuticals Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About TERN Stock
We analyzed Terns Pharmaceuticals Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran TERN through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Moderate. Here's what we found.
TERN Risk Analysis & Red Flags
What Could Go Wrong
The biggest risk is the failure of the Merck acquisition to close, potentially due to regulatory hurdles or an adverse outcome from shareholder investigations. If the deal terminates, TERN's stock price could fall significantly below the current $52.72 to its pre-acquisition levels, which were much lower, eliminating any remaining arbitrage profit.
Risk Matrix
Overall
Moderate
Financial
Low
Market
Low
Competitive
Low
Execution
Medium
Regulatory
High
Red Flags
- ⚠
CEO sold 14,583 shares on March 16, 2026, just nine days before the acquisition announcement, which raises questions about timing and potential perception of value.
- ⚠
Multiple shareholder rights firms are investigating the acquisition, alleging fiduciary duty breaches and an unfair price.
- ⚠
The acquisition price of $53/share offers minimal upside (~0.5%) from the current price, indicating little room for profit and high sensitivity to any deal-related issues.
- ⚠
Previous equity raise in December 2025 caused dilution, and the company is now being sold, suggesting a potential lack of long-term independent value creation.
Upcoming Risk Events
- 📅
Regulatory bodies (e.g., FTC) blocking or delaying the acquisition
- 📅
Shareholder lawsuits causing delays or renegotiation of terms
- 📅
Merck terminating the acquisition agreement
When to Reconsider
- 🚪
Announcement of regulatory bodies blocking the acquisition or requiring significant concessions that change deal terms.
- 🚪
Public statements from Merck indicating a potential termination of the merger agreement.
- 🚪
Significant downward revision of the acquisition price by Merck.
Unlock TERN Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Terns Pharmaceuticals Inc (TERN) Do?
Market Cap
$6.09B
Sector
Healthcare
Industry
Biotechnology
Employees
59
Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates for the treatment of oncology and obesity. The company develops TERN-701, an allosteric BCR-ABL tyrosine kinase inhibitor (TKI) that is in Phase 1 clinical trial for chronic myeloid leukemia (CML), a form of cancer that starts in bone marrow. It also develops TERN-501, a thyroid hormone receptor beta agonist with enhanced liver distribution and metabolic stability that is in Phase IIa clinical trial for the treatment of metabolic dysfunction-associated steatohepatitis (MASH); and TERN-601, a small-molecule Glucagon-Like Peptide-1 receptor agonist program that is intended to orally be administered for obesity, as well as TERN-800 series of small-molecule glucose-dependent insulinotropic polypeptide receptor (GIPR) modulators for obesity. The company was incorporated in 2016 and is headquartered in Foster City, California.
Visit Terns Pharmaceuticals Inc WebsiteInvestment Thesis
The investment thesis for TERN has shifted from a high-growth biotech play to an M&A arbitrage opportunity. The bull case is that Merck's acquisition for $53/share cash closes successfully in Q2 2026, offering a minimal, low-risk return to shareholders who buy below the offer price, assuming no deal breakage.
Is TERN Stock Undervalued?
Unlock the full AI analysis for TERN
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
TERN Price Targets & Strategy
12-Month Target
$53.00
Bull Case
$53.00
Bear Case
$25.00
Valuation Basis
The 12-month target is the agreed acquisition price of $53/share cash from Merck.
Entry Strategy
For arbitrage, buy below $53.00, considering transaction costs and risk of deal termination. Optimal entry would have been prior to the acquisition announcement.
Exit Strategy
Sell at or near $53.00 upon deal closure, or immediately if the acquisition is terminated or delayed indefinitely.
Portfolio Allocation
Less than 1% for very high-risk arbitrage portfolios, as a speculative deal-closure play.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is TERN Financially Healthy?
Valuation
P/E Ratio
-51.06
Price/Book
1.00
Profitability
Return on Equity
-26.25%
Balance Sheet
Current Ratio
30.89
Quick Ratio
30.57
Cash & Equivalents
$334.30M
Other
Beta (Volatility)
0.94
Does TERN Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Eroding (as an independent entity, its IP is being absorbed by Merck)
Moat Sources
1 Identified
TERN's moat was primarily its intellectual property surrounding its drug pipeline. This moat's durability for TERN as a standalone company is now non-existent as it will be subsumed by Merck. However, the assets themselves hold value for Merck.
Moat Erosion Risks
- •Failure of TERN's drug candidates in clinical trials (now Merck's risk)
- •Development of superior treatments by competitors (now Merck's competitive landscape)
TERN Competitive Moat Analysis
Sign up to see competitive advantages
TERN Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral (focused on deal arbitrage, not growth)
Institutional Sentiment
Negative (analyst downgrades to Hold post-deal, reflecting capped upside)
Insider Activity (Form 4)
CEO Amy L. Burroughs sold 14,583 shares on March 16, 2026. CMO Emil Kuriakose sold 942 shares (tax-related RSU vesting) on a recent date. Total insider sales value across 170,409 shares was ~$6.56M.
Options Flow
Normal options activity (likely reflecting arbitrage plays and deal uncertainty).
Earnings Intelligence
Next Earnings
Estimated May 14, 2026 (for Q2 2026)
Surprise Probability
Low (earnings are largely irrelevant for valuation given the acquisition)
Historical Earnings Pattern
Historically a pre-revenue clinical-stage company with losses; post-acquisition announcement, earnings are not a primary driver of stock price.
Key Metrics to Watch
Competitive Position
Top Competitor
N/A (company being acquired)
Market Share Trend
N/A (company being acquired)
Valuation vs Peers
N/A (valuation is now fixed by acquisition price)
Competitive Advantages
- •TERN-701, a highly selective BTK inhibitor for B-cell malignancies (now a Merck asset)
- •Pipeline focused on oncology and NASH (now integrated into Merck's R&D)
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive TERN Stock Higher?
Near-Term (0-6 months)
- •Regulatory clearance for Merck's acquisition (expected Q2 2026 close)
- •Tender offer commencement and successful completion
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for TERN?
- ✓
Official announcement of regulatory approval for the acquisition.
- ✓
News confirming the successful completion of the tender offer.
Bull Case Analysis
See what could go right with Premium
Competing with TERN
See how Terns Pharmaceuticals Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Terns Pharmaceuticals Inc TERN | $6.1B | 1.0 | -51.1 | — | 0.0% | 0.0% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Terns Pharmaceuticals Inc Makes Money
Terns Pharmaceuticals Inc. was a clinical-stage biopharmaceutical company focused on developing novel treatments for oncology and non-alcoholic steatohepatitis (NASH). It did not generate revenue from product sales, instead relying on financing and potential partnerships to fund its research and development pipeline. Its primary value resided in its intellectual property and the potential future commercialization of its drug candidates, such as TERN-701 for chronic myeloid leukemia (CML). This business model was based on advancing drugs through clinical trials to either commercialize them directly or, as now, be acquired by a larger pharmaceutical company.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Terns Pharmaceuticals Inc (TERN)?
As of April 5, 2026, Terns Pharmaceuticals Inc has a DVR Score of 1.0 out of 10, placing it in the "Distressed" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Terns Pharmaceuticals Inc?
Terns Pharmaceuticals Inc's market capitalization is approximately $6.1B. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Terns Pharmaceuticals Inc use?
TERN is the ticker symbol for Terns Pharmaceuticals Inc. The company trades on the NMS.
What is the risk level for TERN stock?
Our analysis rates Terns Pharmaceuticals Inc's overall risk as Moderate. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of TERN?
Terns Pharmaceuticals Inc currently has a price-to-earnings (P/E) ratio of -51.1. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Terns Pharmaceuticals Inc's revenue growing?
Terns Pharmaceuticals Inc has reported revenue growth of 0.0%. Revenue has been declining, which warrants closer examination.
Is TERN stock profitable?
Terns Pharmaceuticals Inc has a profit margin of 0.0%. The company is currently unprofitable.
How often is the TERN DVR analysis updated?
Our AI-powered analysis of Terns Pharmaceuticals Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 5, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for TERN (Terns Pharmaceuticals Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.